R. Frank

Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common CDKN2A Alteration.

P. Stephens, V. Miller, G. Frampton, 2017, The oncologist.

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

K. Owzar, M. Ratain, M. Edelman, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

J. Blay, E. Rasmussen, J. Soria, 2019, Investigational New Drugs.

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

P. Kantoff, N. Stambler, D. Petrylak, 2019, The Prostate.

A phase 2 multicentre study of siltuximab, an anti‐interleukin‐6 monoclonal antibody, in patients with relapsed or refractory multiple myeloma

P. Sonneveld, S. Jagannath, A. Krishnan, 2013, British journal of haematology.

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

G. Shapiro, M. Woo, L. Lewis, 2012, Cancer Chemotherapy and Pharmacology.

Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Keunchil Park, M. Krzakowski, S. Ramalingam, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

(90)Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies.

R. Korn, D. V. Von Hoff, M. Lowery, 2015, European journal of cancer.

Complete response in gallbladder cancer to erlotinib plus gemcitabine does not require mutation of the epidermal growth factor receptor gene: a case report

K. Mody, R. Frank, R. Lincer, 2010, BMC Cancer.

Monitoring of Tumour Glucose Metabolism by PET in a Phase I Study Evaluating Hormonal Therapy in Advanced Pancreatic Cancer

M. Schwaiger, M. Decker, W. Weber, 2002, Scandinavian journal of gastroenterology.